Sarepta Therapeutics, Inc.
SRPT· Nasdaq
SRPTSarepta Therapeutics, Inc.
Filed Aug 4, 2021 · 10-Q · 35 days after period end · 0001564590-21-040787
| Metric | Q2 2021 | Q2 2020 | Q2 2019 | Q2 2018 |
|---|---|---|---|---|
| Revenue | $141.84M | $111.34M | $94.67M | $73.53M |
| Net Income | -$81.41M | -$150.82M | -$276.40M | -$109.27M |
| EPS Diluted | -$1.02 | -$1.93 | -$3.74 | -$1.67 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sarepta Therapeutics, Inc. · CIK 873303 · Engraved from SEC EDGAR
ended Jun 30, 2021 · filed Aug 4, 2021 · 35 d after period end
